Litcius/Paper detail

Discovery of new chiral sulfonamides bearing benzoxadiazole as HIF inhibitors for non-small cell lung cancer therapy: design, microwave-assisted synthesis, binding affinity,<i>in vitro</i>antitumoral activities and<i>in silico</i>studies

Demet Taşdemir Kahraman, Ayşegül Karaküçük‐İyidoğan, Yasemin Saygıdeğer, Emine Elçin Oruç‐Emre, Tuğba Taşkın‐Tok, Eyüp Başaran, Sedat İlhan, Burcu Saygıdeğer Demir, Aykut Üren, Hasan Bayram

2021New Journal of Chemistry12 citationsDOI

Abstract

Thirty-four chiral compounds having benzoxadiazole and sulfonamide moieties on the skeleton have been synthesized. The in vitro cytotoxic activity and apoptotic effects of these compounds have been evaluated using the A549 lung cancer cell line.

Topics & Concepts

ChemistryIn vitroCytotoxic T cellSulfonamideCancer cell linesCancerLung cancerStereochemistryApoptosisPharmacologyCombinatorial chemistryBiochemistryCancer cellOncologyMedicineInternal medicineSynthesis and biological activityEnzyme function and inhibitionQuinazolinone synthesis and applications
Discovery of new chiral sulfonamides bearing benzoxadiazole as HIF inhibitors for non-small cell lung cancer therapy: design, microwave-assisted synthesis, binding affinity,<i>in vitro</i>antitumoral activities and<i>in silico</i>studies | Litcius